CTS attenuation and cross-polarization measurements at 11.7 GHz

The results of data obtained 80 days preceding the solar eclipse shutdown of the CTS 11.7 GHz righthand circularly polarized beacon transmitter are presented. Attenuation and cross polarization isolation were measured. It was determined that depolarization presents a serious limitation to satellite system reliability when frequency reuse by polarization diversity is employed. A 27 db isolation margin would reduce reliability below 99.95%. For the same percentage the required fade margin was below 3 db

ATS-6 attenuation diversity measurements at 20 and 30 GHz

The results of data obtained at The University of Texas at Austin in conjunction with the ATS-6 millimeter wave experiment are presented. Attenuation measurements at 30 GHz and sky noise data at 20 GHz were obtained simultaneously at each of two sites separated by 11 km. Space diversity reduces outage time for a system in Austin, Texas with a 10 dB fade margin at 30 GHz from 15 hours to 16 minutes per year. The maximum cloud height shows a good correlation to the maximum attenuations measured

Monosegment ALPPS hepatectomy preserving segment 4 for colorectal liver metastases : literature review and our experience

Peer reviewedPublisher PD

Swine embryo culture and transfer for export to England

A major threat to swine enterprises is the possible introduction of disease when new breeding animals are purchased and introduced. So, methods of introducing new genetic material while minimizing the potential for introducing disease are needed. Transfer of embryos from a donor sow in another herd or country would minimize disease risks. Already used to introduce new breeding stock into Specific Pathogen Free herds and other closed herds, embryos now are placed in the recipient gilt’s or sow1s uterus within a few hours after their recovery from the donor. That method prevents export and limits application of swine embryo transfer in this country, so we evaluated the feasibility of using an in vitro culture system to store embryos between donor sows and recipient females.; Swine Day, Manhattan, KS, November 8, 197

1940: Abilene Christian College Bible Lectures - Full Text

Delivered in the Auditorium of Abilene Christian College, February, 1940, Abilene, Texas. Published April, 1940 PRICE, $1.00 FIRM FOUNDATION PUBLISHING HOUSE Austin, Texas

Erratum: Author Correction: Identification of genes required for eye development by high-throughput screening of mouse knockouts.

[This corrects the article DOI: 10.1038/s42003-018-0226-0.]

Trastuzumab for HER2-positive early stage breast cancer : a meta-analysis of individual patient data from 13,864 women from seven randomised trials

Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality. Methods: We did a collaborative meta-analysis of individual patient data from randomised trials assessing chemotherapy plus trastuzumab versus the same chemotherapy alone. Randomised trials that enrolled women with node-negative or node-positive, operable breast cancer were included. We collected individual patient-level data on baseline characteristics, dates and sites of first distant breast cancer recurrence and any previous local recurrence or second primary cancer, and the date and underlying cause of death. Primary outcomes were breast cancer recurrence, breast cancer mortality, death without recurrence, and all-cause mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, oestrogen receptor (ER) status, and trial yielded first-event rate ratios (RRs). Findings: Seven randomised trials met the inclusion criteria, and included 13 864 patients enrolled between February, 2000, and December, 2005. Mean scheduled treatment duration was 14·4 months and median follow-up was 10·7 years (IQR 9·5 to 11·9). The risks of breast cancer recurrence (RR 0·66, 95% CI 0·62 to 0·71; p<0·0001) and death from breast cancer (0·67, 0·61 to 0·73; p<0·0001) were lower with trastuzumab plus chemotherapy than with chemotherapy alone. Absolute 10-year recurrence risk was reduced by 9·0% (95% CI 7·4 to 10·7; p<0·0001) and 10-year breast cancer mortality was reduced by 6·4% (4·9 to 7·8; p<0·0001), with a 6·5% reduction (5·0 to 8·0; p<0·0001) in all-cause mortality, and no increase in death without recurrence (0·4%, –0·3 to 1·1; p=0·35). The proportional reduction in recurrence was largest in years 0–1 after randomisation (0·53, 99% CI 0·46 to 0·61), with benefits persisting through years 2–4 (0·73, 0·62 to 0·85) and 5–9 (0·80, 0·64 to 1·01), and little follow-up beyond year 10. Proportional recurrence reductions were similar irrespective of recorded patient and tumour characteristics, including ER status. The more high risk the tumour, the larger the absolute reductions in 5-year recurrence (eg, 5·7% [95% CI 3·1 to 8·3], 6·8% [4·7 to 9·0], and 10·7% [7·7 to 13·6] in N0, N1–3, and N4+ disease). Interpretation: Adding trastuzumab to chemotherapy for early-stage, HER2-positive breast cancer reduces recurrence of, and mortality from, breast cancer by a third, with worthwhile proportional reductions irrespective of recorded patient and tumour characteristics. Funding: Cancer Research UK, UK Medical Research Council